| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9714226 | KARYOPHARM THERAPS | Hydrazide containing nuclear transport modulators and uses thereof |
Jul, 2032
(8 years from now) | |
| US8999996 | KARYOPHARM THERAPS | Hydrazide containing nuclear transport modulators and uses thereof |
Jul, 2033
(9 years from now) | |
| US11807629 | KARYOPHARM THERAPS | Polymorphs of Selinexor |
Aug, 2035
(11 years from now) | |
| US10519139 | KARYOPHARM THERAPS | Polymorphs of Selinexor |
Aug, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9079865 | KARYOPHARM THERAPS | Hydrazide containing nuclear transport modulators and uses thereof |
Jul, 2032
(8 years from now) | |
| US11034660 | KARYOPHARM THERAPS | Hydrazide containing nuclear transport modulators and uses thereof |
Jul, 2032
(8 years from now) | |
| US11787771 | KARYOPHARM THERAPS | Hydrazide containing nuclear transport modulators and uses thereof |
Jul, 2032
(8 years from now) | |
| US10544108 | KARYOPHARM THERAPS | Hydrazide containing nuclear transport modulators and uses thereof |
Jul, 2032
(8 years from now) | |
| US11746102 | KARYOPHARM THERAPS | Polymorphs of selinexor |
Aug, 2035
(11 years from now) | |
| US11753401 | KARYOPHARM THERAPS | Polymorphs of Selinexor |
Aug, 2035
(11 years from now) | |
Xpovio is owned by Karyopharm Theraps.
Xpovio contains Selinexor.
Xpovio has a total of 10 drug patents out of which 0 drug patents have expired.
Xpovio was authorised for market use on 03 July, 2019.
Xpovio is available in tablet;oral dosage forms.
Xpovio can be used as xpovio is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy, xpovio is indicated in combination with dexamethasone to treat relapsed or refractory multiple myeloma (refractory to at least an anti-cd38 mab, 2 proteasome inhibitors and 2 immunomodulatory agents) in adults who received at least 4 prior therapies.
Drug patent challenges can be filed against Xpovio from 04 July, 2023.
The generics of Xpovio are possible to be released after 14 August, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| ODE*(ODE*) | Jul 03, 2026 |
| Orphan Drug Exclusivity(ODE-257) | Jul 03, 2026 |
| New Chemical Entity Exclusivity(NCE) | Jul 03, 2024 |
| Orphan Drug Exclusivity(ODE-310) | Jun 22, 2027 |
| Orphan Drug Exclusivity(ODE-346) | Dec 18, 2027 |
| New Indication(I-837) | Jun 22, 2023 |
Drugs and Companies using SELINEXOR ingredient
NCE-1 date: 04 July, 2023
Market Authorisation Date: 03 July, 2019
Treatment: Xpovio is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy; Xpovio is indicated in comb...
Dosage: TABLET;ORAL
XPOVIO family patents
